United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 15 ml - for the treatment of constipation. in patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

United States - English - NLM (National Library of Medicine)

par pharmaceutical - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 15 ml - for the treatment of constipation. in patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

United States - English - NLM (National Library of Medicine)

chartwell rx, llc. - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose is a synthetic disaccharide in solution form for oral administration. each 15 ml of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g or less of other sugars). also contains water. the ph range is 2.5 to 6.5. lactulose is a colonic acidifier which promotes laxation. the chemical name for lactulose is 4-o-β-d-galactopyranosyl-d-fructofuranose. the molecular formula is c 12 h 22 o 11 . it has the following structural formula: the molecular weight is 342.30. it is freely soluble in water.

Canada - English - Health Canada

pharmascience inc - lactulose - solution - 667mg - lactulose 667mg - ammonia detoxicants

United States - English - NLM (National Library of Medicine)

torrent pharmaceuticals limited - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by the improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml) it is contraindicated in patients who require a low galactose diet.

Malta - English - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - lactulose - oral solution - lactulose 3.35 g/5ml - drugs for constipation

Canada - English - Health Canada

sanis health inc - lactulose - solution - 667mg - lactulose 667mg - ammonia detoxicants

United States - English - NLM (National Library of Medicine)

patrin pharma - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 15 ml

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - lactulose - oral solution - 3.335 g/5ml - osmotically acting laxatives; lactulose

United States - English - NLM (National Library of Medicine)

kesin pharma corporation - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduces the blood ammonia level by 25 to 50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose solution therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.